AstraZeneca Plc expects both sales and core earnings per share to decline again this year as the former blockbuster medicine Crestor loses market share to generic competitors. But the pressure should ease by July as the Crestor losses taper off and new products gain sales momentum, Pascal Soriot, the company’s chief executive, told journalists on 27 April.
